Does margetuximab belong to the ADC antibody drug category?

Margetuximab (margetuximab) does not belong to the ADC (antibody drug conjugate) category, but is a modified monoclonal antibody drug. It is mainly used to treat patients with HER2-positive breast cancer, especially those who are resistant or ineffective to trastuzumab (trastuzumab) treatment. Margetuximab improves anti-tumor activity by enhancing the immune system's recognition and killing of cancer cells, but it does not carry cytotoxic drugs itself, so it is not an ADC.

ADCAntibody drugs refer to a class of drugs that couple antibodies and cytotoxic drugs through chemical linkers. They can accurately deliver more toxic drugs into tumor cells, thereby killing cancer cells and reducing damage to normal cells. Common ADC drugs include T-DM1 (trastuzumab- Maytansine) and T-DXd (trastuzumab-deseptin), these drugs are loaded with chemotherapy drugs on the basis of antibodies and have dual mechanisms of action. In contrast, margetuximab mainly enhances the antibody-dependent cytotoxicity (ADCC) effect by enhancing the binding ability of the Fc segment to immune cells.

Margetuximab is engineered based on the structure of trastuzumab, optimizing the binding ability of the Fc segment to the Fcγ receptor on the surface of immune cells, thereby enhancing the anti-tumor response mediated by natural killer cells (NK cells). This design enables it to achieve better results in partially drug-resistant patients when treating HER2positive breast cancer. Its advantage is to enhance immune-mediated tumor killing rather than directly killing tumor cells.

In summary, margituximab is a modified immunotherapy monoclonal antibody that does not belong to the ADC drug category. It works by enhancing the anti-tumor effects of the immune system, rather than carrying chemotherapy drugs for targeted release. Therefore, when choosing a treatment plan, understanding the difference between it and ADC drugs can help to rationally formulate individualized treatment strategies.

Reference materials:https://www.drugs.com